97029 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants Immunoglobulin superfamily
Sub-classes:METHOD FOR GENERATING NK CELLS
#2USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR
#3ANTI-EGFRVIII ANTIBODIES AND USES THEREOF
#4REAGENTS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASE
#5TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN THE TREATMENT OF CANCER
#6GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#7PRIMERS FOR IMMUNE REPERTOIRE PROFILING
#8ADAPTER-BASED RETROVIRAL VECTOR SYSTEM FOR THE SELECTIVE TRANSDUCTION OF TARGET CELLS
#9FC VARIANTS WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
#10DIRECTED IN VIVO AFFINITY MATURATION OF ANTIBODIES
#11NOVEL CD200 FUSION PROTEINS
#12T-Cell Modulatory Polypeptides and Methods of Use Thereof
#13PLATFORMS, COMPOSITIONS, AND METHODS FOR THERAPEUTIC DELIVERY
#14MRNA Therapies Including SIRP-ALPHA
#15CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE
#16METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#17ANTI-VISTA CONSTRUCTS AND USES THEREOF
#18REVERSIBLE CONTROL OF CHIMERIC ANTIGEN RECEPTOR T CELLS
#19CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
#20METHODS AND MATERIALS FOR TREATING CANCER
#21SIRPalpha-SILENCED NATURAL KILLER (NK) CELLS
#22PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#23METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS
#24COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
#25PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
#26CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#27GD2 BI-SPECIFIC INVARIANT NATURAL KILLER T CELL ENGAGERS AND METHODS OF USE THEREOF
#28COMPOSITIONS AND METHODS OF CHIMERIC ALLOANTIGEN RECEPTOR T CELLS
#29MODIFIED CELLS AND USES THEREOF
#30METHODS FOR TREATING ALZHEIMER'S DISEASE
#31COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS
#32SWITCH COSTIMULATORY RECEPTORS
#33PLACENTA EXPRESSED PROTEINS FOR USE IN THE TREATMENT OF TENDON INJURY
#34RECEPTOR-MEDIATED ENDOCYTOSIS FOR TARGETED INTERNALIZATION AND DEGRADATION OF MEMBRANE PROTEINS AND CARGOS
#35BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#36CONSTRUCTION OF ENGINEERED EXTRACELLULAR VESICLE AND USE THEREOF
#37CANCER ANTIGEN TARGETS AND USES THEREOF
#38COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION
#39COMPOSITIONS AND METHODS OF ACETYCHOLINE RECEPTOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS
#40T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3
#41SWITCH RECEPTORS AND MODIFIED IMMUNE CELLS
#42CD31 MIMETIC COATING FOR ENDOVASCULAR STENT
#43Chimeric Antigen Receptor
#44TREATMENT OF CANCER
#45GENETICALLY ENGINEERED CELLS AND USES THEREOF
#46BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF
#47ENGINEERED IMMUNE CELL WITH CD7 GENE KNOCK-OUT AND USE THEREOF
#48CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE
#49Chimeric Antigen Receptors Targeting HER2
#50METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPalpha BLOCKADE AGENT
#51CLINICAL DOSING OF SIRP1A CHIMERIC PROTEIN
#52EXPRESSION OF NOVEL CELL TAGS
#53COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN FELINES AND METHODS OF USE
#54IMPROVED CELL THERAPIES
#55COMPOSITIONS OF CD47/SIRP-ALPHA IMMUNE CHECKPOINT INHIBITORS AND USES THEREOF
#56METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION
#57GENETICALLY ENGINEERED CELLS, THEIR USES, AND METHODS OF MAKING SAME
#58POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#59MULTIVALENT SIRP-ALPHA FUSION POLYPEPTIDES
#60VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME
#61INTERNAL RIBOSOME ENTRY SITE (IRES), PLASMID VECTOR AND CIRCULAR MRNA FOR ENHANCING PROTEIN EXPRESSION
#62PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
#63GENETICALLY MODIFIED MOUSE MODELS OF ALZHEIMER’S DISEASE
#64ENGINEERED INVARIANT NATURAL KILLER T (INKT) CELLS AND METHODS OF MAKING AND USING THEREOF
#65POLYPEPTIDE ANTIGEN OF BOVINE AND SHEEP PREGNANCY-ASSOCIATED GLYCOPROTEIN AND APPLICATION THEREOF
#66CHIMERIC CYTOKINE RECEPTORS
#67CHIMERIC TIM RECEPTORS AND USES THEREOF
#68COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#69NUCLEIC ACIDS ENCODING SWITCH RECEPTORS USING IL-9 RECEPTOR SIGNALING DOMAINS
#70Modified Butyrophilin and Butyrophilin Complexes
#71METHODS OF CLASSIFYING RESPONSE TO IMMUNOTHERAPY FOR CANCER
#72ARTIFICIAL SYNAPSES
#73ANTI-CD19 AND ANTI-CD79B CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF
#74COMPOSITIONS COMPRISING NKG2D, CXCR2, AND DAP10/DAP12 FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
#75INHIBITION OF TREM RECEPTOR SIGNALING WITH PEPTIDE VARIANTS
#76METHODS COMPRISING ONCOLYTIC VIRUSES EXPRESSING CD19T AND BISPECIFIC T CELL ENGAGERS
#77TREATMENT OF RENAL CELL CARCINOMA
#78COMPOSITIONS AND METHODS FOR TREATING INFECTIOUS DISEASES
#79ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
#80CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
#81Method of modulating autoimmunity by disrupting cis-ligand binding of siglec type antigens
#82SWITCH RECEPTORS USING IL-9 SIGNALING DOMAINS
#83CHIMERIC TIM4 RECEPTORS AND USES THEREOF
#84COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER
#85METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#86POLYCISTRONIC VECTORS FOR CELL-BASED THERAPIES
#87DIAGNOSTIC, PROGNOSTIC, THERAPEUTIC AND SCREENING PROTOCOLS
#88ENGINEERED PD-1 VARIANTS AND METHODS OF USE THEREOF
#89MODIFIED IMMUNE CELLS AND METHODS FOR USE THEREOF
#90COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
#91RECOMBINANT FUSION PROTEIN TARGETING CD40 AND CD47
#92IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF
#93COMPOSITIONS AND METHODS USEFUL IN PROMOTING MILK PRODUCTION
#94DNVSIG3 AND DNVSIG8 RECEPTORS AND METHODS OF USING THE SAME
#95C-KIT ANTIBODIES
#96LILRB POLYPEPTIDES AND USES THEREOF
#97NON-VIRAL B CELL ENGINEERING METHODS
#98IMMUNE CELL COMPOSITIONS AND METHODS OF USE
#99CHIMERIC SWITCH RECEPTORS IN NK CELLS
#100Genetically Modified Hepatocyte Populations
#101SIRPa VARIANT AND USE THEREOF
#102NOVEL PROTEINS
#103TREATMENTS FOR CANCERS UTILIZING CELL-TARGETED THERAPIES AND ASSOCIATED RESEARCH PROTOCOLS
#104METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY
#105Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE)
#106SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#107NATURAL KILLER CELL-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#108HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
#109METHODS FOR THERAPY AND REHABILITATION OF MOVEMENT DISORDERS
#110COMPOUND CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
#111ENHANCEMENT OF CD47 BLOCKADE THERAPY WITH DHFR INHIBITORS
#112BCMA CHIMERIC ANTIGEN RECEPTORS
#113NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
#114MODIFIED STEM CELL COMPOSITIONS AND METHODS FOR USE
#115DHFR TUNABLE PROTEIN REGULATION
#116CD47/PD-L1-TARGETING PROTEIN COMPLEX AND METHODS OF USE THEREOF
#117ANTIBODIES FOR SIGLEC-15 AND METHODS OF USE THEREOF TO TREAT DISUSE OSTEOPOROSIS
#118FUSION PROTEIN DIMER INCLUDING PD-1 AND IL-21, AND USE THEREOF
#119NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3
#120CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#121NUCLEIC ACID CONSTRUCT
#122CHIMERIC ENGULFMENT RECEPTOR MOLECULES
#123GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE
#124INHIBITORY CHIMERIC ANTIGEN RECEPTORS
#125NOVEL FAB DIMERS
#126HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE
#127COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS
#128TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
#129CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF
#130TISSUE-DIRECTED ANTIBODIES AND METHODS OF USING THE SAME
#131ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USE THEREOF
#132BUTYROPHILIN-LIKE 2 AGENTS FOR TREATING INFLAMMATORY DISORDERS
#133COMPOSITIONS AND METHODS COMPRISING CAR T CELLS COMPRISING PRDM1 AND/OR NR4A3 KNOCKOUT
#134CAR T/NK-CELLS FOR USE IN THE TREATMENT OF INVASIVE FUNGAL INFECTIONS
#135METHOD FOR IDENTIFYING T-CELL EPITOPE SEQUENCE, AND APPLICATION OF SAME
#136TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
#137ALTERED EXPRESSION OF Y CHROMOSOME-LINKED ANTIGENS IN HYPOIMMUNOGENIC CELLS
#138CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS
#139GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND MOUSE TREM2 P.R47H AND METHODS OF USE THEREOF
#140MANIPULATED IMMUNOREGULATORY ELEMENT AND IMMUNITY ALTERED THEREBY
#141USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE
#142HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS
#143CLAUDIN18.2 CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
#144REAGENTS AND METHODS FOR TREATING CANCER AND AUTOIMMUNE DISEASE
#145HIDE1 COMPOSITIONS AND METHODS
#146SYNTHETIC RECEPTOR FOR CONDITIONAL ACTIVATION OF IMMUNE CELLS
#147CHIMERIC TIM RECEPTORS AND USES THEREOF
#148TCRS SPECIFIC FOR MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
#149SIGLEC-9 ECD Fusion Molecules and Methods of Use Thereof
#150TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
#151CAR-T CELL THERAPY FOR TRIPLE NEGATIVE BREAST CANCER
#152ULTRAHIGH-AFFINITY SMALL PROTEIN TARGETING PD-L1 AND USE
#153CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS
#154MODIFIED GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) AND CHIMERIC CYTOKINE RECEPTORS BINDING SAME
#155FUSION PROTEINS OF PD-1 AND 4-1BB
#156LAG-3 PROTEIN MUTANT, AND PREPARATION AND USE THEREOF
#157CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY
#158TCR MIMIC MONOCLONAL ANTIBODIES REACTIVE WITH THE PHOSPHO-NEOANTIGEN PIRS2/HLA-A*02:01 COMPLEX AND USES THEREOF
#159Hypoimmunogenic Biotherapeutics
#160VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
#161Programmed Cell Death Protein 1 (PD1) Compositions and Methods for Cell-Based Therapy
#162GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS
#163CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES
#164ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#165METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS
#166CAR-T CONSTRUCTS COMPRISING A NOVEL CD19 BINDER COMBINED WITH IL18 AND METHODS OF USING THE SAME
#167CHIMERIC POLYPEPTIDES, NUCLEIC ACID MOLECULES, CELLS, AND RELATED METHODS
#168EGFRVIII BINDING PROTEINS
#169METHODS TO IMPROVE T CELL EFFICACY AND SAFETY BY MODULATING MEDIATORS OF PHAGOCYTOSIS
#170NKP30 RECEPTOR TARGETED THERAPEUTICS
#171THERAPEUTIC COMPOSITIONS COMPRISING MICROBE-TARGETING MOLECULES AND THEIR USE IN METHODS OF PREVENTING AND TREATING INFECTIOUS DISEASE
#172ANTIGEN RECOGNIZING RECEPTORS TARGETING CD33 AND USES THEREOF
#173CHIMERIC ANTIGEN RECEPTORS, NUCLEIC ACIDS ENCODING THE SAME, AND USES THEREOF IN TREATING CANCERS
#174CHIMERIC ANTIGEN RECEPTOR THAT RECOGNIZES CCR8 AS ANTIGEN
#175ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30
#176CHIMERIC APOPTOTIC SIGNAL TARGETING LYMPHOCYTES (TIM-4 CASTL) AND METHODS OF MAKING AND USING SAME
#177SYNTHETIC INTERMEMBRANE PROTEOLYSIS RECEPTORS FOR CUSTOM ANTIGEN-INDUCED TRANSCRIPTIONAL REGULATION
#178CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
#179T CELL REGULATION
#180HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE
#181GENERATION OF CD3 EXPRESSING IMMUNE CELLS FOR USE IN CONJUNCTION WITH CD3 BINDING BISPECIFIC TARGETING AGENTS
#182NANOCARRIERS FOR TARGETING TUMOR ASSOCIATED MACROPHAGES
#183SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS
#184NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF
#185COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY
#186METHODS TO PROTECT TRANSPLANTED TISSUE FROM REJECTION
#187BI-SPECIFIC TARGETED CHIMERIC ANTIGEN RECEPTOR T CELLS
#188POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#189RECOMBINANT TIM-4 PROTEIN, CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL DELIVERY SYSTEM AND METHODS OF MAKING AND USING SAME
#190Improved T cell receptor-costimulatory molecule chimera
#191CHIMERIC PHAGOCYTIC RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
#192SYSTEMS AND METHODS FOR PROTEIN EXPRESSION
#193NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE
#194VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF
#195GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS
#196CUSTOMIZED CHIMERIC ANTIGEN RECEPTOR POLYPEPTIDES
#197ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#198CAR-T CONSTRUCTS COMPRISING A NOVEL CD19 BINDER COMBINED WITH IL18 AND METHODS OF USING THE SAME
#199METHODS AND COMPOSITIONS FOR CELLULAR THERAPY
#200IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
#201Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
#202ONCOLYTIC VIRUS FOR SYSTEMIC DELIVERY AND ENHANCED ANTI-TUMOR ACTIVITIES
#203MODIFIED STEM CELL COMPOSITIONS AND METHODS FOR USE
#204STEM CELL IN WHICH IMMUNE CELL TOLERANCE MODULATOR IS OVEREXPRESSED, AND USE THEREOF
#205CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND NK CELLS EXPRESSING CAR CONSTRUCTS
#206Crohn's Disease-Associated T Cell Receptor-Related Methods
#207CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY
#208REGULATORS OF B CELL-MEDIATED IMMUNOSUPPRESSION
#209PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS
#210TREATMENT OF CONGENITAL STATIONARY NIGHT BLINDNESS USING GENE THERAPY
#211Compositions and methods for immunotherapy
#212GENETIC ENGINEERING OF MACROPHAGES FOR IMMUNOTHERAPY
#213CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE
#214METHODS FOR PREVENTING FUNGAL INFECTIONS
#215KHL POLYPEPTIDE, AND USE THEREOF IN PREPARATION OF TABP-EIC CELL
#216CD7-TARGETED ENGINEERED IMMUNE CELL, CHIMERIC ANTIGEN RECEPTOR, CD7 BLOCKING MOLECULE AND USE THEREOF
#217CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
#218CHIMERIC TIM4 RECEPTORS AND USES THEREOF
#219SYSTEMS AND METHODS TO LINK CD40 SIGNALING TO ANTIGEN BINDING
#220METHODS OF BLOCKING / NEUTRALIZING ASFV INFECTION THROUGH INTERRUPTION OF CELLULAR AND VIRAL RECEPTOR INTERACTIONS
#221CD200 INHIBITORS AND METHODS OF USE THEREOF
#222Cell
#223CELL
#224Method for generating t-cells compatible for allogenic transplantation
#225PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
#226RAGE PROTEINS FOR THE TREATMENT OF FIBROSIS AND DNA DAMAGE MEDIATED DISEASES
#227NK CELLS OR T CELLS EXPRESSING CHIMERIC HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE
#228CHIMERIC ANTIGEN RECEPTOR
#229COMBINATION THERAPIES FOR TREATING UROTHELIAL CARCINOMA
#230PD1-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
#231Preparation of therapeutic exosomes using membrane proteins
#232CHIMERIC ANTIGEN RECEPTOR COMPRISING NOVEL CO-STIMULATORY DOMAIN AND USE THEREOF
#233Oncolytic virus vector and application thereof
#234GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
#235METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE
#236Methods and compositions for modulating CAR-T activity
#237ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY
#238CELL-PENETRATING PEPTIDES
#239HOMODIMERIC AND HETERODIMERIC PROTEINS COMPRISING BUTYROPHILIN
#240Allograft tolerance without the need for systemic immune suppression
#241METHODS OF IDENTIFYING GAMMA DELTA T CELL-MODULATING AGENTS
#242METHODS FOR STIMULATING PROLIFERATION OR DIFFERENTIATION OF AN IMMUNE CELL WITH A MULTI-CHAIN CHIMERIC POLYPEPTIDE
#243Destroying Cancer Cells While Maintaining Healthy Cell Integrity
#244CHIMERIC ANTIGEN RECEPTOR WITH MODIFIED HINGE REGION AND USES THEREOF
#245T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy
#246CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#247METHODS OF TREATING AGING-RELATED DISORDERS
#248BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#249COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
#250SIRP-ALPHA FUSION POLYPEPTIDES WITH MODIFIED FC DOMAINS
#251METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS
#252Inhibition of TREM receptor signaling with peptide variants
#253CD38-BINDING CD31 PEPTIDES AND USES THEREOF
#254DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY
#255SOLUBLE CD33 FOR TREATING MYELODYSPLASTIC SYNDROMES (MDS)
#256BIOLOGICAL MACROMOLECULAR TARGET-SPECIFIC COMPLEMENT INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#257MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#258Chimeric Antigen Receptor
#259SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#260PEPTIDES AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
#261COMPOSITIONS AND USES OF CD45 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
#262SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES
#263HYBRID PROMOTERS, VECTORS CONTAINING SAME AND METHODS OF USE
#264FUSION PROTEIN ENHANCING CELL THERAPY
#265COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS
#266CD47 BINDER AND LIPOSOME COMPLEX FOR CANCER TREATMENT
#267CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY
#268NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS
#269ARTIFICIAL SYNAPSES
#270MYELIN OLIGODENDROCYTE GLYCOPROTEIN-SPECIFIC PEPTIDE FOR THE TREATMENT OR PREVENTION OF MULTIPLE SCLEROSIS
#271Switch receptors using IL-9 signaling domains
#272CHIMERIC ANTIGEN RECEPTORS (CARs), TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF
#273SOLUBLE THY-1 COMPOSITIONS AND USE THEREOF TO TREAT OR REVERSE FIBROSIS
#274STRENGTHENED RECEPTOR FOR IMPROVING IMMUNE CELL FUNCTION
#275T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#276COMPOSITIONS AND METHODS FOR MODULATION OF SIRPALPHA-MEDIATED SIGNALING
#277SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS
#278GENE THERAPIES FOR LYSOSOMAL DISORDERS
#279MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
#280PRIMERS FOR IMMUNE REPERTOIRE PROFILING
#281METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
#282ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF
#283Nucleic acids encoding switch receptors using IL-9 receptor signaling domains
#284METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER
#285FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF
#286LIGHT-INDUCIBLE GENE ACTIVATION SYSTEMS AND METHODS FOR MAKING AND USING THEM
#287Methods of permeabilizing the blood brain barrier
#288NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS
#289PD-L1 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#290C-KIT antibodies and method for treating cancer with such
#291IMMUNE CELLS OVEREXPRESSING CELL SIGNALING REGULATORY FACTOR INTRODUCED FROM OUTSIDE AND USE THEREOF
#292RAGE Fusion Proteins with Improved Stability and Ligand Binding Affinity and Uses Thereof
#293MODIFIED NATURAL KILLER CELLS AND METHODS OF USING THE SAME
#294PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS
#295BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOF
#296CONDITIONALLY ACTIVE CHIMERIC ANTIGEN RECEPTORS FOR MODIFIED T-CELLS
#297POLYPEPTIDE USEFUL IN ADOPTIVE CELL THERAPY
#298ANTIBODY GENE EDITING IN B LYMPHOCYTES AND CO-EXPRESSION OF CARGO PROTEIN
#299BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES
#300MULTISPECIFIC ANTI-FLT3 CHIMERIC ANTIGEN RECEPTORS